This article is free to access.
Background: Angiogenesis, among other signaling pathways, plays a key-role in sarcoma biology. Regorafenib (RE) has recently been shown to be effective in imatinib and sunitinib-refractory GIST in a phase III trial. Methods/design: We are conducting an international trial (France, Austria and Germany) consisting in 4 parallel double-blind placebo-controlled randomized (1/1) phase II trials to assess the activity and safety of RE in doxorubicin-refractory STS (ClinicalTrials.gov: NCT01900743). Each phase II trial is dedicated to one of the 4 following histological subgroups: liposarcoma, leiomyosarcoma, synovial sarcoma and other sarcoma. Within each randomized trial the following stratification factors will be applied: countries and prior exposure to pazopanib. Key-eligibility criteria are: measurable disease, age ≥18, not>3 previous systemic treatment lines for metastatic disease, metastatic disease not amenable to surgical resection. The primary endpoint is progression-free survival (PFS) according to central radiological review. Secondary endpoints are: Toxicity (NCI-CTC AE V4.0); time to progression; Growth modulation index in pts receiving RE after randomization; 3 and 6months PFS-Rates, best response rate and overall survival. Each phase II trial will be separately analyzed. In 3 trials, statistical assumptions are: PFS0=1.6 & PFS1=4.6months; 1-sided α=0.1; β=0.05 with a total sample size of 192 pts. To take into account the rarity of synovial sarcoma, the statistical assumptions are: PFS0=1.6 & PFS1=4.6months; 1-sided α=0.1; β=0.2 Tumor assessment is done monthly during the 4 first months, and every 3months thereafter. After central radiological confirmation of tumor progression, an optional open-label option is offered to eligible patients. Discussion: The design of this trial allows an assessment of regorafenib activity over placebo in four sarcoma strata and might provide evidence for launching a phase III trial. This study includes both integrative and exploratory translational research program. The study is enrolling since June 2013 (Trial Registration Number: EudraCT N°: 2012-005743-24, on the 15th February 2012).
Brodowicz, T., Liegl-Atzwager, B., Tresch, E., Taieb, S., Kramar, A., Gruenwald, V., … Penel, N. (2015). Study protocol of REGOSARC trial: Activity and safety of regorafenib in advanced soft tissue sarcoma: A multinational, randomized, placebo-controlled, phase II trial. BMC Cancer, 15(1). https://doi.org/10.1186/s12885-015-1143-y